The LBT solution is an innovative new treatment for improved prognosis in Acute Myocardial Infarction. The LBT treatment is a Non-Invasive and completely safe treatment which uses external laser activation to immobilize stem-cells into the blood circulation. These activated stem-cells home on the MI scar and reverses the scarring process.
LBT is showing good initial results in minimizing scarring during Acute Myocardial Infarction, in Gastroenterology and recently - in Neurological conditions (such as Alzheimer's disease).
Our treatment device (CardioZ16 Laser Device), is a laser which is brought into contact with the skin overlying a marrow containing bone. The laser emits light to stimulate the marrow to engender tissue repair at a location in the body that is remote from the bone. LLLT has been shown to have a photobiostimulatory effect on stem cells. LBT completed the in-vivo stage and have shown that applying LLLT to bone marrow in pigs, rats and mice post-myocardial infarction caused a marked reduction of scar tissue formation in the heart.
We aim to translate this cutting-edge cell-therapy activation by LLLT, into clinical products and treatments that extend and improve the quality of life of individuals suffering from acute and chronic diseases. LBT currently focuses on treatment of Acute Myocardial Infarction (acute MI). In the future, we intend to explore additional indications, such as Thyroid Hormone Resistance (THR), Traumatic Brain Injury (TBI), and Alzheimer's disease.
LBT is currently seeking interaction with key opinion leaders (KOLs), as well as R&D collaboration with leading medical institutions. Our management team, led by co-Founder and CEO Alon Sinai, has a vast experience in the industry in LLLT, R&D, clinical development, entrepreneurship and business development. LBT is based in Israel, a world-class hub for biomedical innovation.
We believe that this is the future worthy of intensive research and investment.